| oxaliplatin / Generic mfg. |
| Not yet recruiting | 3 | 100 | | | Epworth HealthCare, Epworth HealthCare | Pancreatic cancer | | | | |
SHR-A1811-309, CTR20234257: A randomized, open-label, active-controlled, multicenter phase III clinical study of SHR-A1811 for injection versus investigator-selected treatment regimen in patients with advanced colorectal cancer who have failed treatment with oxaliplatin, fluorouraci |
|
|
| Ongoing | 3 | 120 | China | trastuzumab rezetecan (SHR-A1811) - Jiangsu Hengrui Pharma, Lonsurf (trifluridine/tipiracil) - Servier, Otsuka, Stivarga (regorafenib) - Bayer, Fruzaqla (fruquintinib) - Takeda | Shanghai Hengrui Pharmaceutical Co., Ltd./ Jiangsu Hengrui Pharmaceutical Co., Ltd./ Suzhou Shengdia Biopharmaceutical Co., Ltd | Colorectal cancer | | | | |
ChiCTR-TRC-12002734: S-1 plus oxaliplatin (SOX) versus fluorouracil and folinic acid plus oxaliplatin (mFOLFOX6) for first-line treatment of patients with metastatic colorectal cancer: a randomised controlled trial |
|
|
| Completed | 3 | 360 | | S-1 plus oxaliplatin ;fluorouracil and folinic acid plus oxaliplatin | West China Hospital, Sichuan University; Shandong New Time（age） Pharmaceutical Co., LTD, Shandong New Time (age) Pharmaceutical Co., LTD | Shandong New Time (age) Pharmaceutical Co., LTD | | | | |
2007-007059-14: Role of the Glutatione reduced in the prevention of neuro-toxicity from Oxaliplatino. Ruolo del Glutatione ridotto nella prevenzione della neurotossicita' da Oxaliplatino. |
|
|
| Ongoing | 3 | 180 | Europe | Powder and solvent for solution for infusion | AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI | Patients with neoplasia malignant. Pazienti con neoplasia maligna. | | | | |
NCT00705029: Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer |
|
|
| Recruiting | 3 | 244 | US | alpha-lipoic acid, placebo | University of Medicine and Dentistry New Jersey, M.D. Anderson Cancer Center, Jarrow Formulas Inc | Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific | 01/09 | | | |
2008-000837-23: mEOC: Chemotherapy in chemonaïve patients with mucinous ovarian cancer |
|
|
| Ongoing | 3 | 336 | Europe | Carboplatin, Paclitaxel, Oxaliplatin, Capecitabine, , Solution for infusion, Concentrate for solution for infusion, Tablet, Avastin | University College London, POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI, , Roche | Mucinous ovarian cancer, stages II-IV and stage I recurrent, MUCINOUS OVARIAN CANCER CARCINOMA MUCINOSO OVAIO, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
ChiCTR-TRC-08000061: Randomized controlled trial on the treatment of advanced gastric cancer by POF and IF regimes |
|
|
| Recruiting | 3 | 200 | | Irinotecan 80 mg/m2 ivgtt. for 30 minutes, formyltetrahydrofolate 500 mg/m2 ivgtt. for 2 hours; and then use fluorouracil 2000 mg/m2 ivgtt. for 22 hours. The treatment is given once a week for 6 weeks and repeated after a week's interval. ;Taxol 135 mg/m2 ivgtt. for 3 hours; then use formyltetrahydrofolate 400 mg/m2 ivgtt. for 2 hours and oxaliplatin 85 mg/m2 ivgtt. for 2 hours; and then use fluorouracil 2400 mg/m2 ivgtt. for 46 hours. One treatment cycle lasts 14 days. | Fujian Provincial Tumor Hospital; Fujian Anti-cancer Association, Fujian Anti-cancer Association | Gastric Cancer | | | | |
2011-004406-25: Etude randomisée de phase III comparant une radiochimiothérapie préopératoire à une chimiothérapie néoadjuvante Folfirinox suivie de radiochimiothérapie préopératoire pour les patients atteints de cancers du rectum localement avancés (étude PRODIGE-GERCOR-SFRO-GRECCAR) |
|
|
| Not yet recruiting | 3 | 460 | Europe | OXALIPLATINE, IRINOTECAN, ACIDE FOLINIQUE, 5-FLUOROURACILE, Solution for injection/concentrate for solution for infusion, Powder and solution for solution for injection, ELOXATINE, CAMPTO, ELVORINE, 5-FLUOROURACIL | UNICANCER, PHRC | Adénocarcinome du rectum, Cancer du rectum, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 263 | Europe, US | bleomycin sulfate, cisplatin, etoposide, ifosfamide, oxaliplatin, paclitaxel | UNICANCER | Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor | 03/12 | 12/24 | | |
2011-005003-32: A study comparing the effect of chemotherapy with the effect of chemotherapy plus local removal of metastases for patients with cancer of the large bowel which has spread to multiple organs. |
|
|
| Ongoing | 3 | 478 | Europe | capecitabin, oxaliplatin, bevacizumab, fluorouracil, Folinic acid, Film-coated tablet, Concentrate for solution for infusion, Concentrate for solution for injection/infusion, Solution for injection/infusion, Xeloda, Eloxatin, Avastin, Fluorouracil, Sodiofolin | VU University Medical Center, Department of Medical Oncology, VU University Medical Center, Department of Medical Oncology | multi-organ metastatic colorectal cancer, Patients with metastases of large bowel cancer in multiple organs, Diseases [C] - Cancer [C04] | | | | |
LOGiC, NCT00680901 / 2007-005725-29: - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib |
|
|
| Active, not recruiting | 3 | 545 | Europe, Canada, US, RoW | Lapatinib, Tykerb, Tyverb, Placebo, Capecitabine, Oxaliplatin | Novartis Pharmaceuticals | Neoplasms, Gastrointestinal Tract | 09/12 | 01/25 | | |
|
|
|
2012-005748-12: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study INTERET DE LA CHIMIOHYPERTHERMIE INTRAPERITONEALE (CHIP) ADJUVANTE A L’OXALIPLATINE DANS LE TRAITEMENT CURATIF DES CANCERS GASTRIQUES AVANCES. ETUDE NATIONALE, RANDOMISEE ET MULTICENTRIQUE DE PHASE III. |
|
|
| Ongoing | 3 | 322 | Europe | 5 Fluorouracilo, L01B1A, Solution for injection/infusion, Oxaliplatin, 5 Fluorouracilo, Levofolinate Calcium | Hospices Civils de Lyon, Ministère de la Santé, Hospices Civils de Lyon | Gastric adenocarcinoma, Stomach cancer, Diseases [C] - Digestive System Diseases [C06] | | | | |
2013-003244-23: Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI Studio che mette a confronto, come trattamento di prima linea del tumore metastatico del colon-retto, il Bevacizumab + FOLFIRI seguito da Bevacizumab + FOLFOX (o XELOX) oppure la squenza inversa Bevacizumab + FOLFOX ( o XELOX) seguito da Bevacizumab + FOLFIRI contro la terapia standard che prevde Bevacizumab + FOLFIRI. |
|
|
| Ongoing | 3 | 400 | Europe | Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Powder for infusion, Avastin, CAMPTO, OXALIPLATINO, XELODA, FLUOROURACILE TEVA, LEVOFOLENE | S.I.C.O.G. ONLUS, S.I.C.O.G. ONLUS | Unresectable and metastatic colorectal cancer carcinoma del colon-retto inoperabile e metastatico, Advanced tumour of colon/rectum Tumore avanzato del colon-retto, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-12002121: Preventive use of lamivudine in postgastrectomy adenocarcinoma patients carrying HBV to prevent from severe liver damage and viral activation |
|
|
| Completed | 3 | 60 | | lamivudine ;Radiotherapy combined with Chemotherapy that contains oxaliplatin | West China Hospital, Sichuan University; Level of the institution：, Hospital funding | gastric cancer and HBV | | | | |
2014-004436-19: Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment line Studio di fase III per confrontare due diversi trattamenti chemioterapici per valutare se la prima linea con tre farmaci + bevacizumab seguita da una seconda linea con lo stesso schema terapeutico possa fornire risultati migliori rispetto a un trattamento con due farmaci + bevacizumab sia nella prima che nella seconda linea di trattamento |
|
|
| Ongoing | 3 | 654 | Europe | Bevacizumab, 5 Fluorouracile, Irinotecan, Oxaliplatino, acido levo-folinico (L-Leucovorin), Bevacizumab, 5 Fluorouracile, Irinotecan, Oxaliplatino, acido levo-folinico (L-Leucovorin), Concentrate for solution for infusion, Solution for infusion, Powder for solution for infusion, Avastin, FLUOROURACILE TEVA* 500mg/10 ml, IRINOTECAN TEVA* 20 mg/ml, OXALIPLATINO TEVA* 5 mg/ml, LEDERFOLIN PFIZER* 25 mg | G.O.N.O., Roche S.p.A. | METASTATIC COLORECTAL CANCER Carcinoma colorettale metastatico (mCRC), metastatic tumor of colon-rectum, Diseases [C] - Cancer [C04] | | | | |
NCT01081262: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer |
|
|
| Active, not recruiting | 3 | 50 | US | Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment | National Cancer Institute (NCI), NRG Oncology | Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7 | 02/15 | 03/25 | | |
|
2013-003047-29: BALLAD UK- a trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma |
|
|
| Ongoing | 3 | 120 | Europe | Fluorouracil, Folinic Acid, Capecitabine, Oxaliplatin, Solution for injection/infusion, Film-coated tablet, Solution for infusion | Greater Glasgow and Clyde Health Board, University of Glasgow, CRUK | Small Bowel Adenocarcinoma, Small Bowel Adenocarcinoma, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-12002919: A randomized phase III trial of concurrent chemoradiotherapy consisting of S-1 and oxaliplatin (SOX) in gastric cancer with radical D2 lymph node dissection |
|
|
| Recruiting | 3 | 620 | | concurrent chemoradiotherapy ;chemoradiotherapy | Department of medical oncology, Cancer Center, West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financed | gastric cancer | | | | |
2011-001858-28: A clinical trial for people who have cancer of the food pipe and junction of the food pipe and stomach, to compare chemotherapy before and after surgery, with chemotherapy with radiotherapy before surgery. |
|
|
| Ongoing | 3 | 378 | Europe | Epirubicin, Cisplatin, 5 Fluorouracil, Capecitabine, Paclitaxel, Carboplatin, Oxaliplatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin | ICORG, ICORG- All Ireland Cooperative Oncology Research Group, ICORG, | Adenocarcinoma of the oesophagus and oesophago-gastric junction | | | | |
2013-004952-39: Chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases The CHARISMA randomized multicenter clinical trial Chemotherapie gevolgd door chirurgie versus chirurgie alleen in hoog-risico patienten met resectabele colorectale levermetastasen De CHARISMA gerandomiseerde multicenter trial |
|
|
| Ongoing | 3 | 224 | Europe | Oxaliplatin, Xeloda/Capecitabine, Oxaliplatin, Xeloda / Capecitabine, Oxaliplatin, Xeloda / Capecitabine | Erasmus MC Cancer Institute, KWF Kankerfonds | Colorectal liver metastases Colorectale levermetastasen | | | | |
| Recruiting | 3 | 300 | | Maintain with capecitabine after XELOX or FOLFOX treatment ;XELOX or FOLFOX | West China Hospital，Sichuan University; West China Hospital，Sichuan University, No-funds | advanced colorectal cancer | | | | |
2016-002331-16: Comparaison d'un traitement par FOLFOX (Oxaliplatine et 5 FU) et du traitement par TFOX (oxaliplatine + 5 FU et Docetaxel) chez les patients ayant un cancer de l'estomac ou de la jonction entre estomac et oesophage localement avancé ou métastatique |
|
|
| Not yet recruiting | 3 | 506 | Europe | Solution for infusion, TAXOTERE | Fédération Francophone de Cancérologie Digestive, Fédération Francophone de Cancérologie Digestive | Cancer de l'estomac et de la jonction oeso-gastrique localement avancé ou métastatique, Patient présentant un cancer de l'estomac ou de la jonction estomac-oesophage localement avancé ou avec des métastases, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-13003139: Paclitaxel plus S-1 (TS) versus oxaliplatin and S-1(SOX) for treatment of advanced diffuse-type gastric cancer: a multicenter, randomised ,controlled trial |
|
|
| Recruiting | 3 | 238 | | Paclitaxel plus S-1 ;Oxaliplatin plus S-1 | West China Hospital; Level of the institution：, self-funded | advanced diffuse-type gastric cancer | | | | |
2016-004394-40: FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico. |
|
|
| Ongoing | 3 | 432 | Europe | Panitumumab, Fluorouracile, Oxaliplatino, Calcio Levofolinato, Irinotecan, [Panitumumab], [Fluorouracile], [Oxaliplatino], [Calcio Levofolinato], [Irinotecan], Solution for infusion, VECTIBIX - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 20 ML, FLUOROURACILE AHCL - 50MG/ML SOLUZIONE INIETTABILE O INFUSIONE 1 FLACONCINO IN VETRO DA 100 ML, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, CALCIO LEVOFOLINATO TEVA - 25 MG POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, IRINOTECAN CSC - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML | Fondazione GONO, Amgen, G.O.N.O. | Metastatic Colorectal Cancer Carcinoma Colorettale metastatico, colorectal cancer spread at distance tumore al colon retto diffuso a distanza, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-11001560: A multi-center clinical trail for Tegafur, gimeracil and oteracil potassium capsules combined with Oxaliplatin in treatment of phase II, IIIa gastric cancer |
|
|
| Recruiting | 3 | 240 | | Tegafur, Gimeracil and Oteracil Potassium Capsules 40 mg/m2, B.i.d P.O.; Oxaliplatin 130 mg/m2, d1-14, integrated in 5% GS 250 ml, ivgtt 120/min; repeated every 3 weeks ;Tegafur, Gimeracil and Oteracil Potassium Capsules 40 mg/m2, B.i.d ,P.O., d1-14; repeated evey 3 weeks | Henan Cancer Hospital; iang Shu Heng Rui Medicine Company Limited By Shares. No. 7, Kunlun mountain Road, Lianyungang Economic and Technological Development Zone, Jiangshu, China, Jiang Shu Heng Rui Medicine Company Limited By Shares | gastric cancer | | | | |
2016-002272-27: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy. |
|
|
| Ongoing | 3 | 388 | Europe | Opdivo, Solution for injection, Opdivo | Saarland University, Bristol-Myers Squibb | Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2017-002036-17: The (cost)effectiveness of preoperative chemotherapy versus preoperative gemcitabine based chemoradiotherapy and adjuvant gemcitabine in patients with pancreatic cancer. |
|
|
| Ongoing | 3 | 368 | Europe | Leucovorin calcium, Fluorouracil, Irinotecan, Oxaliplatin, Powder for solution for injection/infusion, Solution for infusion, Concentrate for solution for infusion, LEUCOVORIN CALCIUM, Fluorouracil, Irinotecan, Oxaliplatin | Erasmus Medical Center, ZonMw, KWF | (borderline) resectable pancreatic cancer, (possible) resectable pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
2018-000377-68: Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas |
|
|
| Ongoing | 3 | 218 | Europe | Paclitaxel in cationic liposomes, EndoTAG-1, Powder and solvent for concentrate for solution for infusion | SynCore Biotechnology Co., Ltd., SynCore Biotechnology Co., Ltd. | Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Diseases [C] - Cancer [C04] | | | | |
2014-002517-39: Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more ETUDE DE PHASE III RANDOMISEE EVALUANT LA CHIMIOTHERAPIE ADJUVANTE APRES RESECTION D’UN ADENOCARCINOME COLIQUE DE STADE III CHEZ LES PATIENTS DE 70 ANS ET PLUS |
|
|
| Ongoing | 3 | 982 | Europe | Solution for infusion, Film-coated tablet, Fluorouracil Accord Healthcare 50 mg/ml, solution pour injection ou perfusion, Elvorine 25 mg/2,5 ml solution injectable Elvorine 50 mg/5 ml solution injectable, Xeloda 150 mg comprimés pelliculés. Xeloda 500 mg comprimés pelliculés., ELOXATIN 5 mg/ml solution à diluer pour perfusion | Fédération Francophone de Cancérologie Digestive (FFCD), FFCD itself, Belgian Group Digestive Oncology( BGDO) | Adjuvant treatment in stage III adenocarcinoma of the colon fully resected for patient of 70 years and over Traitement adjuvant d'un adénocarcinome colique de stade III totalement réséqué chez les patients de 70 ans et plus, Adjuvant treatment in stage III adenocarcinoma of the colon fully resected for patient of 70 years and over Traitement adjuvant d'un adénocarcinome colique de stade III totalement réséqué chez les patients de 70 ans et plus, Diseases [C] - Cancer [C04] | | | | |
2018-002886-21: A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma. |
|
|
| Not yet recruiting | 3 | 210 | Europe | Powder for concentrate for solution for infusion, Concentrate for solution for infusion | UNICANCER, Programme hospitalier de recherche clinique (PHRC) | Metastatic Pancreatic Ductal Adenocarcinoma, Advanced pancreas cancer, Diseases [C] - Cancer [C04] | | | | |
2018-002831-65: BALLAD BELGIUM: A trial to evaluate the potential benefit of adjuvant chemotherapy, that means a chemotherapy in addition to the curative surgery for small bowel adenocarcinoma |
|
|
| Ongoing | 3 | 30 | Europe | Solution for infusion, Film-coated tablet, Fluorouracil Accord Healthcare 50 mg/ml, solution pour injection ou perfusion, Elvorine 25 mg/2,5 ml solution injectable Elvorine 50 mg/5 ml solution injectable, Xeloda 150 mg comprimés pelliculés, Xeloda 500 mg comprimés pelliculés, ELOXATIN 5 mg/ml solution à diluer pour perfusion | Belgian Group of Digestive Oncology (BGDO), Belgian Group of Digestive Oncology (BGDO) | small bowel adenocarcinoma, SMALL BOWEL ADENOCARCINOMA, Diseases [C] - Cancer [C04] | | | | |
PRODIGY, NCT01515748: Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer |
|
|
| Completed | 3 | 530 | RoW | Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) | Sanofi | Gastric Cancer | 01/19 | 12/21 | | |
SVOSA, NCT02338518: Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients |
|
|
| Active, not recruiting | 3 | 297 | RoW | oxaliplatin, etoposide, pharmorubicin, epirubicin, S-1 | Jinling Hospital, China | Stomach Neoplasms, Gastric Cancer | 05/19 | 10/23 | | |
PRODIGE 23, NCT01804790: Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 461 | Europe | mFolfirinox, Radiotherapy 50 Gy, Capecitabine, TME surgery, mFolfox6 or capecitabine | UNICANCER | Cancer of the Rectum | 09/19 | 05/25 | | |
2019-001364-30: Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX |
|
|
| Not yet recruiting | 3 | 400 | Europe | Oxaliplatin, Folinic acid, 5-Fluorouracil, Gemcitabine, Solution for infusion, Powder for solution for infusion | Assistance Publique- Hôpitaux de Paris | Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 2000 | Europe | FOLFOX regimen, folinic acid, infusional fluorouracil, and oxaliplatin, CAPOX, capecitabine plus oxaliplatin; XELOX | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer | 01/20 | 12/23 | | |
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients |
|
|
| Recruiting | 3 | 477 | RoW | transanal surgery, Miles surgery, Preoperative chemoradiotherapy | Zhang Rui | Almost-cCR, Surgery, Rectal Cancer | 01/20 | 12/22 | | |
2018-001728-20: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ). Neoadjuvante Radiochemotherapie versus Chemotherapie für Patienten mit lokal fortgeschrittenem, potentiell resektablen Adenokarzinom des ösophagogastralen Übergangs. |
|
|
| Not yet recruiting | 3 | 340 | Europe | 5-Fluorouracil, Calcium Folinate, Oxaliplatin, Docetaxel, Solution for injection, Solution for solution for injection | Ruprecht-Karls-Universität Heidelberg, Deutsche Krebshilfe | Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ), Locally advanced resectable gastric cancer, Diseases [C] - Cancer [C04] | | | | |
2018-000876-14: ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients A randomized phase III trial of the German Rectal Cancer Study Group |
|
|
| Not yet recruiting | 3 | 702 | Europe | 5-fluorouracil, Oxaliplatin, Capecitabine, folinic acid, Solution for infusion, Concentrate for solution for infusion, Tablet | University Hospital Frankfurt, Goethe University, German Cancer Aid | Locally advanced rectal cancer (UICC stage II and III), Rectal cancer, Diseases [C] - Cancer [C04] | | | | |
CALGB, NCT01150045: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery |
|
|
| Active, not recruiting | 3 | 2527 | Canada, US | celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 02/20 | | | |
| Active, not recruiting | 3 | 920 | Europe, US | M1 scheme, standard long course chemoradiotherapy | University Medical Center Groningen, Karolinska University Hospital, Leiden University Medical Center, Uppsala University Hospital, Dutch Cancer Society | Rectal Cancer | 03/20 | 12/26 | | |
NCT03511963: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC |
|
|
| Active, not recruiting | 3 | 677 | RoW | HLX04 100 mg in 4 ml Injection, Avastin 100 mg in 4 ml Injection | Shanghai Henlius Biotech | Metastatic Colorectal Cancer (mCRC) | 04/20 | 04/24 | | |
2020-000149-15: Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus. |
|
|
| Not yet recruiting | 3 | 1020 | Europe | Carboplatin, Paklitaxel, Cisplatin, 5-fluorouracil, Oxaliplatin, Calcium folinate, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for injection/infusion | Karolinska University Hospital, Karolinska University Hospital, Swedish Research Council | Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, Cancer in the gullet (esophagus), which is possible to operate., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 2031 | Europe, Canada, Japan, US, RoW | Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 05/20 | 05/24 | | |
|
|
|
|
|
|
2020-002141-42: Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study Toevoeging van inductie chemotherapie aan de voorbehandeling van patiënten met lokaal teruggekeerde endeldarmkanker - de PelvEx II studie |
|
|
| Not yet recruiting | 3 | 364 | Europe | Capecitabine Accord, Oxaliplatin Accord, 5-Fluorouracil, Leucovorine Sandoz, Irinotecan, Infusion, Tablet, Oxaliplatin, Capecitabine, 5-fluorouracil, Leucovorin, Irinotecan | Catharina Hospital, Instituto Português de Oncologia de Lisboa Francisco Gentil – EPE, Catharina Ziekenhuis Eindhoven, ZonMW, ZonMw, Catharina Ziekenhuis Eindhoven | Locally recurrent rectal cancer Lokaal recidief rectum carcinoom, Locally recurrent rectal cancer Lokaal teruggekeerde endeldarmkanker, Diseases [C] - Cancer [C04] | | | | |
2017-003832-35: Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma – The phase III “PREVENT” trial of the AIO /CAOGI /ACO |
|
|
| Not yet recruiting | 3 | 200 | Europe | Docetaxel, Oxaliplatin, 5-fluorouracil, Leucovorin, Cisplatin, Concentrate for solution for infusion, Solution for injection | Institute of Clinical Cancer Research (IKF) Krankenhaus Nordwest, Deutsche Krebshilfe | locally advanced resectable diffuse type adenocarcinoma of the oesophagogastric junction or the stomach, locally advanced resectable diffuse type gastric cancer, Diseases [C] - Cancer [C04] | | | | |
2018-001356-35: FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure |
|
|
| Not yet recruiting | 3 | 550 | Europe | 5-Fluorouracil, Oxaliplatin, Leucovorin, Capecitabin, Solution for injection, Concentrate and solvent for solution for infusion, Tablet, Oxaliplatin, Leucovorin, Capecitabin | University of Heidelberg, German Cancer Aid | Locally advanced rectal adenocarcinoma localized 0 - 16 cm from the anal verge with low risk of local failure, Locally advanced rectal cancer with low risk of local failure, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 214 | RoW | Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen, HAIC Regimen, Oral Sorafenib | Sun Yat-sen University | Hepatocellular Carcinoma | 10/20 | 06/22 | | |
2016-002393-12: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first-line treatment of metastatic colorectal cancer restricted to the liver Chimiothérapie par oxaliplatine en intra-veineux ou dans le foie combiné à une chimiothérapie par LV5FU2 ± Irinotécan, et une thérapie ciblée, en intraveineux chez des patients ayant un cancer colorectal métastatique limité au foie. |
|
|
| Not yet recruiting | 3 | 348 | Europe | Solution for infusion, ELOXATINE | Fédération Francophone de Cancérologie Digestive, AMGEN | colorectal cancer with hepatic metastasis Cancer colorectal métastatique au niveau hépatique, colon cancer and rectal cancer with liver metastasis cancer du côlon ou du rectum avec métastases au niveau du foie, Diseases [C] - Cancer [C04] | | | | |
SONCAR, NCT02031939: Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 556 | RoW | Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin), standard chemoradiotherapy | Sun Yat-sen University | Advanced Rectal Cancer | 12/20 | 12/25 | | |
| Recruiting | 3 | 570 | RoW | KL-140, Placebo | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Metastatic Colorectal Cancer | 12/20 | 12/23 | | |
NCT03415763: Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy |
|
|
| Recruiting | 3 | 764 | RoW | Capecitabine, Xeloda, mFOLFOX6 or CAPOX, 5-Fu-leucovorin-oxaliplatin or xeloda-oxaliplatin | LI XIN-XIANG | Rectal Neoplasms | 12/20 | 12/25 | | |
NCT03355612: XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma |
|
|
| Not yet recruiting | 3 | 456 | NA | Apatinib, YN968D1, XELOX, Capecitabine and Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Carcinoma | 12/20 | 12/25 | | |
NCT03448549: SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients |
|
|
| Recruiting | 3 | 1191 | RoW | Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda, Capecitabine | Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University People's Hospital | Colorectal Cancer Stage III, Adjuvant Chemotherapy | 01/21 | 01/24 | | |
2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-5) |
|
|
| Ongoing | 3 | 350 | Europe, RoW | Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin, ADCT-402, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, TRUXIMA, Bendacitabin 38 mg/ml, Oxali-Bendalis 5 mg/ml | ADC Therapeutics SA, ADC THERAPEUTICS SA, ADC Therapeutics SA | Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma, Diseases [C] - Cancer [C04] | | | | |
| Completed | 3 | 830 | Europe | Induction chemotherapy with gemcitabine or FOLFIRINOX, all brands of gemcitabine and FOLFIRINOX components are allowed, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine, all brands of gemcitabine are allowed, Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy | University of Erlangen-Nürnberg Medical School | Pancreatic Cancer | 02/21 | 11/23 | | |
KEYNOTE-177, NCT02563002 / 2015-002024-89: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/) |
|
|
| Completed | 3 | 307 | NA | mFOLFOX6, FOLFIRI, pembrolizumab, IV infusion, bevacizumab, cetuximab | Merck Sharp & Dohme LLC | Colorectal Carcinoma | 02/21 | 07/23 | | |
|
|
|
|
|
CONVERT, NCT02288195: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients |
|
|
| Active, not recruiting | 3 | 663 | RoW | Oxaliplatin, Eloxatin, capecitabine, Xeloda, Radiation, radiotherapy | Sun Yat-sen University, Shantou Central Hospital, Liaoning Tumor Hospital & Institute, The First Affiliated Hospital with Nanjing Medical University, Fujian Cancer Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial People's Hospital, Cancer Hospital of Guangxi Medical University, Meizhou People's Hospital, Henan Cancer Hospital, Affiliated Cancer Hospital of Shantou University Medical College, Hubei Cancer Hospital, First Affiliated Hospital of Kunming Medical University, Longyan City First Hospital, Shengjing Hospital, Zhejiang Cancer Hospital, Jiangmen Central Hospital, West China Hospital, The Third Affiliated Hospital of Kunming Medical College. | Rectal Neoplasms | 03/21 | 03/24 | | |
2019-004582-40: TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer |
|
|
| Ongoing | 3 | 184 | Europe | Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, Paclitaxel, Gemcitabine, Concentrate for solution for infusion | Amsterdam UMC-Location AMC-dept. Internal Medicin, University of Amsterdam | Metastasized pancreatic cancer Gemetastaseerd pancreas carcinoom, Metastasized pancreatic cancer Uitgezaaide alvleesklierkanker, Diseases [C] - Cancer [C04] | | | | |
OPTICAL, NCT02572141: FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Active, not recruiting | 3 | 738 | RoW | Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens, Oxaliplatin, 5-Fluorouracil, Capecitabine, Leucovorin, Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens | Sun Yat-sen University | Colon Cancer | 04/21 | 04/23 | | |
TNTCRT, NCT03177382: Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors |
|
|
| Recruiting | 3 | 458 | RoW | Total neoadjuvant treatment, TNT, concurrent chemoradiotherapy, CRT, TME, Adjuvant chemotherapy | West China Hospital | Total Neoadjuvant Treatment, Chemoradiotherapy, Local Advanced Rectal Cancer, High Risk Factors | 05/21 | 05/23 | | |
| Active, not recruiting | 3 | 464 | Europe, RoW | FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche | Colorectal Cancer Metastatic | 07/23 | 12/24 | | |
ORIENT-16, NCT03745170: Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer |
|
|
| Completed | 3 | 650 | RoW | Sintilimab, IBI308, Oxaliplatin, Capecitabine, placebo | Innovent Biologics (Suzhou) Co. Ltd. | Gastric Cancer | 06/21 | 10/22 | | |
|
2020-005141-16: Chemotherapy before or after surgery in patients with resectable pancreatic cancer: the PREOPANC-3 study. |
|
|
| Not yet recruiting | 3 | 378 | Europe | Leucovorin calcium, Fluorouracil, Irinotecan, Oxaliplatin, Powder for solution for injection/infusion, Solution for infusion, Concentrate for solution for infusion, LEUCOVORIN CALCIUM, Fluorouracil, Irinotecan, Oxaliplatin | Erasmus MC, Erasmus MC | non-metastatic resectable pancreatic cancer, non-metastatic resectable pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
EPAC1, NCT03199989: Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors |
|
|
| Recruiting | 3 | 1254 | RoW | CapeOX（Capecitabine+Oxaliplatin）, Observation | Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Peking University People's Hospital | Adjuvant Chemotherapy | 07/21 | 07/24 | | |
2021-000317-17: Survival analysis after pre-surgical therapy in patients with resectable pancreatic cancer and risk factors ANÁLISIS DE SUPERVIVENCIA TRAS TRATAMIENTO ANTES DE LA CIRUGÍA EN CÁNCER DE PÁNCREAS RESECABLE CON FACTORES DE RIESGO |
|
|
| Ongoing | 3 | 116 | Europe | Irinotecan, Fluorouracil, Oxaliplatin, calcium folinate, Concentrate for solution for injection/infusion, Solution for infusion | Fundación para la Gestión de la Investigación Biomédica de Cádiz-INIBICA, Instituto de Salud Carlos III | Resectable pancreatic cancer and risk factors Cáncer de pancreas resecable con factores de riesgo, Non-operable pancreatic cancer plus other conditions that increase the possibility to adquire a disease Cancer de pancreas no operable mas otras condiciones que aumenten la posibilidad de adquirir una enfermedad, Diseases [C] - Cancer [C04] | | | | |
2020-006144-18: Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer Prospektive, randomisierte, offene, multizentrische Phase III Studie zur Untersuchung der Wirksamkeit einer Therapie in Patienten mit metastasiertem kolorektalen Karzinom, nach erfolgter Resektion oder Ablation |
|
|
| Not yet recruiting | 3 | 507 | Europe | 5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Solution for solution for injection, Concentrate and solvent for solution for infusion, Solution for injection, Concentrate for solution for infusion, Oxaliplatin, Leucovorin | Charité Universitätsmedizin Berlin, DFG - Deutsche Forschungsgemeinschaft e.V. | Metastatic colorectal cancer after definite interventional therapy of all lesions, Metastatic colorectal cancer after therapy of lesions, Diseases [C] - Cancer [C04] | | | | |
2020-004906-79: A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma Studie zur Wirksamkeit einer Chemotherapie nach Operation beim Karzinom der Bauchspeicheldrüse, wobei die Zuteilung zur Oxaliplatin-basierten oder Gemcitabin-basierten Chemotherapie entweder nach klinischen Standardkriterien oder nach genetischen Markern erfolgt |
|
|
| Not yet recruiting | 3 | 394 | Europe | Gemcitabine, Capecitabine, 5-fluorouracil, Irinotecan, Calcium Folinate, Oxaliplatin, Powder for solution for infusion, Film-coated tablet, Solution for injection, Concentrate for solution for infusion, Solution for injection/infusion | Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg, Dietmar Hopp Stiftung, Cancerforskningsfonden i Norrland | Resected pancreatic ductal adenocarcinoma operiertes duktales Pankreas-Adenokarzinom, Resected pancreatic ductal adenocarcinoma operiertes duktales Bauchspeicheldrüsen-Adenokarzinom, Diseases [C] - Cancer [C04] | | | | |
APEC, NCT02965248: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer ( Study) |
|
|
| Recruiting | 3 | 147 | RoW | Standard adjuvant systemic chemotherapy, adjuvant oxaliplatin, 5-FU, and leucovorin calcium (mFOLFOX6), adjuvant oxaliplatin and capecitabine (CapeOx), adjuvant 5-FU and leucovorin calcium (sLV5FU2), adjuvant capecitabine (Cape), Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed, Intraperitoneal raltitrexed 3 mg/m2, Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin, I.V. leucovorin calcium 20 mg/m2, I.V. 5-FU 400 mg/m2, Intraperitoneal oxaliplatin 130 mg/m2 | Fudan University | Locally Advanced Colorectal Cancer | 11/21 | 11/23 | | |
NCT02087475: Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin |
|
|
| Recruiting | 3 | 360 | RoW | Irinotecan, 5-fluorouracil, Local radiotherapy, R0 resection | Sixth Affiliated Hospital, Sun Yat-sen University | Colorectal Neoplasms, Effects of Chemotherapy, Surgery, Metastasis, Local Neoplasm Recurrence | 12/21 | 12/24 | | |
ARMANI, NCT02934464: Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers |
|
|
| Recruiting | 3 | 280 | Europe | RAMUCIRUMAB, Cyramza, Paclitaxel, FOLFOX 4, Oxaliplatino + l-leucovorin + 5 Fluorouracile, mFOLFOX 6, XELOX, Oxaliplatino + Capecitabina | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Stomach Neoplasms | 12/21 | 12/21 | | |
NCT03788226: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer |
|
|
| Recruiting | 3 | 600 | RoW | POF, CAPOX/SOX/FOLFOX | Fujian Cancer Hospital | Gastric Cancer Stage III | 12/21 | 12/23 | | |
NCT04303429: Adjuvant Chemotherapy in High Risk Stage II Colon Cancer |
|
|
| Not yet recruiting | 3 | 962 | NA | FOLFOX/XELOX/Capecitabine | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Stage II Colon Cancer, Adjuvant Chemotherapy | 01/22 | 01/25 | | |
| Completed | 3 | 171 | Europe | Gemcitabine, Folinic Acid, 5-Fluoro-uracil, Oxaliplatin, Irinotecan, L-folinic | UNICANCER | Pancreatic Cancer, Carcinoma | 02/22 | 09/23 | | |
NCT03813784: A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer |
|
|
| Active, not recruiting | 3 | 887 | RoW | SHR-1210, Capecitabine, Oxaliplatin, Apatinib | Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, GastroEsophageal Cancer | 02/22 | 03/23 | | |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 564 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 02/22 | 02/24 | | |
| Active, not recruiting | 3 | 649 | Europe, Japan, US, RoW | Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, BGB-A317, Placebo | BeiGene | Esophageal Squamous Cell Carcinoma (ESCC) | 02/22 | 06/24 | | |
|
|
|
NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
NCT03125980: Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Recruiting | 3 | 1370 | RoW | capecitabine plus oxaliplatin before and after surgery, capecitabine plus oxaliplatin after surgery | Fudan University | Locally Advanced Colon Cancer | 05/22 | 05/27 | | |
CAIRO4, NCT01606098: The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer |
|
|
| Completed | 3 | 206 | Europe | Surgery of the primary tumour, Systemic treatment, Bevacizumab in combination with fluoropyrimidine-based schedules | Dutch Colorectal Cancer Group, Hoffmann-La Roche | Colon Cancer, Primary Tumour, Rectal Cancer | 06/22 | 12/22 | | |
GRECCAR12, NCT02514278: Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy |
|
|
| Active, not recruiting | 3 | 218 | Europe | Neoadjuvant chemotherapy Folfirinox, 4 cycles, 50 Gy, 2 Gy/session; 25 fractions, Local excision in good responders, Rectal excision in bad responders, Capecitabine | University Hospital, Bordeaux | Rectal Cancer | 06/22 | 06/24 | | |
ChiCTR2000034867: A multicenter, randomized, double-blind, placebo-controlled phase III clinical study on the prevention of peripheral neurotoxicity of oxaliplatin by yiqiwenjing recipe |
|
|
| Not yet recruiting | 3 | 360 | | Oxaliplatin containing chemotherapy combined with placebo ;Adjuvant chemotherapy combined with yiqiwenjing prescription I called Huangqi Guizhi Wuwu granules. ;Adjuvant chemotherapy combined with yiqiwenjing prescription II called Danggui Sini granules. | Jiangsu Province Hospital on Integration Chinese and Western Medicine; Jiangsu Province Hospital on Integration Chinese and Western Medicine, Jiangsu Provincial Department of science and technology, provincial key research and development program (Social Development) project: No:BE2019767 | Peripheral neurotoxicity of oxaliplatin | | | | |
YWPPEOPNCT, NCT04690283: Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial |
|
|
| Not yet recruiting | 3 | 360 | NA | Mimetic granules of Yiqi-Wenjing prescriptions, Mimetic granules of Huangqi-Guizhi-Wuwu plus Danggui-Sini decoction, Huangqi-Guizhi-Wuwu granules, Danggui-Sini granules | Nanjing NingQi Medicine Science and Technology Co., Ltd., Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Cancer Institute & Hospital, Fudan University | Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer | 07/22 | 10/22 | | |
UNION, NCT04928807: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 231 | RoW | Short course radiotherapy sequential camrelizumab and chemotherapy | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Rectal Cancer | 03/23 | 03/26 | | |
| Recruiting | 3 | 564 | Europe | FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab | Dutch Colorectal Cancer Group | Colorectal Cancer, Liver Metastases | 08/22 | 07/25 | | |
KL140-Ⅲ-02-CTP, NCT04835142: Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC |
|
|
| Recruiting | 3 | 686 | RoW | Double blind control period A140, KL-140, Open single period A140 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Metastatic Colorectal Cancer | 08/22 | 04/23 | | |
NCT03851913: The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy |
|
|
| Recruiting | 3 | 344 | RoW | TAI | Sun Yat-sen University | Hepatocellular Carcinoma | 08/22 | 08/24 | | |
NCT04516681: IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 400 | RoW | Ascorbic acid, Vitamin C, FOLFOXIRI Protocol, FOLFOXIRI+/- bevacizumab | Fudan University | Colorectal Cancer, Vitamin C, GLUT3 | 09/22 | 09/23 | | |
NCT03961867: Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 440 | RoW | Docetaxel, S-1, Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | Gastric Cancer | 09/22 | 09/25 | | |
NCT04384601: Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer |
|
|
| Not yet recruiting | 3 | 246 | RoW | Chemotherapy, FLOT chemotherapy, SOX chemotherapy | Ruijin Hospital | Gastric Cancer, Neoadjuvant Chemotherapy | 09/22 | 09/27 | | |
Spotlight, NCT03504397 / 2017-002567-17: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer |
|
|
| Active, not recruiting | 3 | 566 | Europe, Canada, Japan, US, RoW | zolbetuximab, IMAB362, placebo, oxaliplatin, folinic acid, fluorouracil | Astellas Pharma Global Development, Inc. | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 09/22 | 03/25 | | |
|
CRTCOESC, NCT02025036: Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer |
|
|
| Active, not recruiting | 3 | 249 | RoW | Capecitabine(Aibin), Aibin, Oxaliplatin(Aiheng), Aiheng, Radiotherapy, Radiation Therapy | The First Affiliated Hospital of Henan University of Science and Technology, Luoyang Central Hospital, Military 150 Hospital, Anyang Cancer Hospital, Nanyang Central Hospital, Henan Oncology Hospital, The First Affiliated Hospital of Xinyang Medical College, Sanmenxia Central Hospital | Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma | 09/22 | 04/25 | | |
NCT06190782: Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor |
|
|
| Recruiting | 3 | 354 | RoW | PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone, the systemic therapy only | Fudan University | Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy | 09/25 | 09/27 | | |
| Active, not recruiting | 3 | 1579 | Europe, Canada, Japan, US, RoW | Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, PLATINOL®, 5-fluorouracil, ADRUCIL®, 5FU, oxaliplatin, ELOXATIN®, capecitabine, XELODA®, Placebo for Pembrolizumab | Merck Sharp & Dohme LLC | Stomach Neoplasms | 10/22 | 03/25 | | |
|
GLOW, NCT03653507 / 2018-000519-26: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 507 | Europe, Canada, Japan, US, RoW | zolbetuximab, IMAB362, oxaliplatin, capecitabine, placebo | Astellas Pharma Global Development, Inc. | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 10/22 | 03/25 | | |
|
NCT03678428: FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM |
|
|
| Terminated | 3 | 92 | RoW | Irinotecan, Oxaliplatin HAI, Floxuridine, Leucovorin, 5-FU, Oxaliplatin | Sun Yat-sen University | Metastatic Colorectal Cancer, Liver Metastases | 10/22 | 12/22 | | |
NCT03399253: Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor |
|
|
| Recruiting | 3 | 120 | RoW | surgery, chemotherapy, XELOX | Sun Yat-sen University | Gastric Cancer | 11/22 | 12/25 | | |
AGENT, NCT03750786 / 2017-004154-41: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer |
|
|
| Completed | 3 | 490 | Europe, Canada, Japan, US, RoW | Arfolitixorin, Leucovorin | Isofol Medical AB | Colo-rectal Cancer | 11/22 | 11/22 | | |
NCT03399110: XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) |
|
|
| Active, not recruiting | 3 | 1032 | RoW | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | Fudan University | Gastric Cancer | 08/26 | 08/26 | | |
NCT04667351: HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial |
|
|
| Recruiting | 3 | 400 | RoW | 2400 mg/m² 5-fu, 1200 mg/m² 5-fu | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital | HepatoCellular Carcinoma | 12/22 | 12/22 | | |
